Cantor Fitzgerald Issues Positive Outlook for Amgen Earnings

Amgen Inc. (NASDAQ:AMGN) – Research analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Amgen in a report released on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now expects that the medical research company will post earnings of $20.90 per share for the year, up from their previous estimate of $20.85. Cantor Fitzgerald has a “Neutral” rating and a $305.00 price objective on the stock. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share. Cantor Fitzgerald also issued estimates for Amgen’s FY2026 earnings at $21.47 EPS.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The company had revenue of $8.15 billion for the quarter, compared to analysts’ expectations of $8.05 billion. During the same quarter in the previous year, the firm posted $3.96 EPS. The firm’s quarterly revenue was up 9.4% on a year-over-year basis.

A number of other equities research analysts have also recently weighed in on AMGN. William Blair restated an “outperform” rating on shares of Amgen in a report on Tuesday, June 24th. Royal Bank Of Canada reduced their target price on Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. Piper Sandler reaffirmed an “overweight” rating and issued a $328.00 target price on shares of Amgen in a research note on Friday, June 27th. Mizuho upped their target price on Amgen from $235.00 to $280.00 and gave the company a “neutral” rating in a research note on Wednesday, May 7th. Finally, Wall Street Zen raised Amgen from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 18th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $307.82.

Amgen Stock Performance

AMGN opened at $300.37 on Thursday. The stock has a market cap of $161.51 billion, a P/E ratio of 27.41, a P/E/G ratio of 2.68 and a beta of 0.49. The company has a debt-to-equity ratio of 8.70, a current ratio of 1.17 and a quick ratio of 0.88. The stock’s 50 day simple moving average is $283.28 and its 200 day simple moving average is $287.76. Amgen has a 1-year low of $253.30 and a 1-year high of $346.85.

Institutional Trading of Amgen

Several large investors have recently modified their holdings of AMGN. Capital World Investors grew its stake in shares of Amgen by 1,292.0% during the fourth quarter. Capital World Investors now owns 6,495,710 shares of the medical research company’s stock valued at $1,693,042,000 after acquiring an additional 6,029,058 shares in the last quarter. Norges Bank acquired a new position in Amgen in the fourth quarter worth about $1,541,991,000. GAMMA Investing LLC grew its stake in Amgen by 43,573.5% in the first quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company’s stock worth $1,140,768,000 after purchasing an additional 3,653,205 shares in the last quarter. Capital International Investors grew its stake in Amgen by 40.1% in the fourth quarter. Capital International Investors now owns 12,212,065 shares of the medical research company’s stock worth $3,182,843,000 after purchasing an additional 3,495,503 shares in the last quarter. Finally, Nuveen LLC acquired a new position in Amgen in the first quarter worth about $688,868,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 1,500 shares of the firm’s stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the sale, the senior vice president directly owned 8,162 shares in the company, valued at $2,364,368.16. This trade represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.76% of the stock is owned by corporate insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.